McKesson Corporation reported its fiscal 2025 second quarter results, revealing an adjusted net income of $915 million, surpassing the $891.8 million estimate. The company reported a revenue of $93.65 billion, exceeding the expected $89.33 billion. Adjusted earnings per share (EPS) for the quarter reached $7.07, compared to the forecast of $6.88. Following these results, McKesson raised its full-year adjusted EPS guidance to a range of $32.40 to $33. The increase in guidance was attributed to robust demand in its U.S. pharmaceuticals segment, particularly for specialty and branded drugs. Additionally, McKesson received an upgrade to 'Outperform' from Baird, with a price target of $688.